AbbVie v EMA: Humira study reports provide 'roadmap' for competitors
This article was originally published in SRA
The EU judge who granted interim injunctions preventing the European Medicines Agency from releasing data on AbbVie’s Humira and InterMune’s Esbriet says there are “complex and delicate” questions to be discussed regarding the balance between commercial interests and the public interest. Moreover, he suggests that even when these interests have been properly weighed, it is “not obvious… that the balance will be clearly in favour of the public interest defended by the EMA”1,2.
You may also be interested in...
The MHRA is losing no time in getting its much heralded “new era” of medicines regulation up and running.
Coronavirus Notebook: EMA Issues Guidance On Development Of Variant Vaccines, EU Leaders Urge Production Ramp-Up
A batch of AstraZeneca/Oxford University coronavirus vaccines has arrived in Ghana, the first country in the world to receive vaccines via the COVAX Facility.
At current rates, not enough coronavirus vaccines will be manufactured in 2021 or even 2022 to meet global demand or achieve global population immunity, according to a new dataset that monitors vaccine supply agreements around the world.